Mizuho keeps an Outperform rating on Neumora Therapeutics (NMRA) after the company announced negative first Phase 3 KOASTAL-1/K-1 study data for navacaprant in major depressive disorder. With navacaprant missing on both primary and secondary endpoints, a disappointing outcome, the stock’s 80% drop is not surprising, the analyst tells investors in a research note. The firm reminds investors that Neumora has two more shots on goal with navacaprant, with the Phase 3 KOASTAL-2/K-2 and KOASTAL-3/ K-3 studies ongoing, and data readouts from both expected in the first half of 2025. With Neumora now trading at negative enterprise value, but having a cash runway to mid-2026 and other pipeline programs, the shares look oversold, contends Mizuho.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- H.C. Wainwright still sees opportunity for Neumora despite trial miss
- Tesla reports below-consensus deliveries: Morning Buzz
- RBC downgrades Neumora Therapeutics to Sector Perform after trial failure
- Neumora Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Neumora Therapeutics Inc trading resumes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
